Clinical trials: Part 1：r/r B-cell Malignancies
Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Orelabrutinib (ICP-022) in Patients with B-cell malignancies.
- Trial name
- NCT04014205
- Testing
- Orelabrutinib (ICP-022)
- Where
- 36 sites in United States, Israel and 2 more
- Volunteers
- 81 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.